MedTrace Logo

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

NCT02133989 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2017-04-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior than clopidogrel in terms of post-stent ischemic lesions in these patients without serious complications.

Conditions

  • Carotid Stenosis

Interventions

DRUG

Ticlopidine + Ginko biloba

ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily

DRUG

Clopidogrel

clopidogrel bisulfate 97.875mg(75mg as clopidogrel)

Sponsors & Collaborators

  • Yuyu Pharma, Inc.

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Oh Young Bang, MD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133989 on ClinicalTrials.gov